Current Report Filing (8-k)
September 17 2019 - 8:10AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report: September 12, 2019
(Date of earliest event reported)
ImmuCell
Corporation
(Exact name of registrant as specified in its charter)
|
DE
|
|
001-12934
|
|
01-0382980
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification Number)
|
|
56
Evergreen Drive
Portland,
Maine
|
|
04103
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
207-878-2770
(Registrant’s telephone number, including area code)
Not
Applicable
(Former Name or Former Address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant
under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act: None
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item
1.01. Entry into a Material Definitive Agreement
On
September 12, 2019, ImmuCell Corporation (the Company) entered into a lease covering approximately 14,300 square feet of office
and warehouse space effective approximately November 1, 2019. The space will be utilized to enable the Company’s plan to
increase the production capacity of the First Defense® product line. The full text of the press release
issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The
information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange
Act”) or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
The
following exhibits relating to Item 1.01 shall be deemed to be furnished, and not filed:
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
IMMUCELL
CORPORATION
|
|
|
|
|
Date:
September 17, 2019
|
By:
|
/s/
Michael F. Brigham
|
|
|
|
Michael
F. Brigham
|
|
|
|
President,
Chief Executive Officer and
Principal Financial Officer
|
Exhibit
Index
3
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Apr 2023 to Apr 2024
